Lee Ji Hye, Kim Jin-Young, Choi Jae Sung, Na Ju Ock
Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Choenan, Republic of Korea.
Tuberc Respir Dis (Seoul). 2022 Oct;85(4):283-288. doi: 10.4046/trd.2022.0097. Epub 2022 Aug 16.
Asthma is a chronic inflammatory disease of the airways characterized by varying and recurrent symptoms, reversible airway obstruction, and bronchospasm. In this paper, clinical important studies on asthma published between March 2021 and February 2022 were reviewed. A study on the relationship between asthma and chronic rhinosinusitis, bronchiectasis, and hormone replacement therapy was published. A journal on the usefulness of fractional exhaled nitric oxide for the prediction of severe acute exacerbation was also introduced. Studies on the effect of inhaler, one of the most important treatments for asthma, were published. Studies on the control of severe asthma continued. Phase 2 and 3 studies of new biologics were also published. As the coronavirus disease 2019 (COVID-19) pandemic has been prolonged, many studies have explored the prevalence and mortality of COVID-19 infection in asthma patients.
哮喘是一种气道慢性炎症性疾病，其特征为症状多变且反复发作、气道可逆性阻塞以及支气管痉挛。本文回顾了2021年3月至2022年2月间发表的有关哮喘的重要临床研究。一项关于哮喘与慢性鼻-鼻窦炎、支气管扩张和激素替代疗法之间关系的研究已发表。还介绍了一篇关于呼出气一氧化氮分数对预测严重急性加重的有用性的期刊文章。有关哮喘最重要治疗方法之一的吸入器效果的研究已发表。关于重度哮喘控制的研究仍在继续。新型生物制剂的2期和3期研究也已发表。由于2019冠状病毒病（COVID-19）大流行持续存在，许多研究探讨了哮喘患者中COVID-19感染的患病率和死亡率。
